Expression of androgen receptor in inflammatory breast cancer and its clinical relevance

Authors

  • Yun Gong MD,

    Corresponding author
    1. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    2. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas
    • Corresponding author: Yun Gong, MD, Department of Pathology, Unit 53, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030; Fax: (713) 794-5664; yungong@mdanderson.org

    Search for more papers by this author
  • Wei Wei MS,

    1. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Search for more papers by this author
  • Yun Wu MD, PhD,

    1. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Search for more papers by this author
  • Naoto T. Ueno MD, PhD,

    1. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas
    2. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Search for more papers by this author
  • Lei Huo MD, PhD

    1. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    2. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Search for more papers by this author

  • Presented at the 100th Annual Meeting of the United States and Canadian Academy of Pathology; San Antonio, Texas; February 26 to March 4, 2011.

  • We thank Tamara K. Locke from the Department of Scientific Publications at The University of Texas MD Anderson Cancer Center for editing this article.

Abstract

BACKGROUND

Inflammatory breast cancer (IBC) is characterized by an aggressive clinical course with early metastasis and frequent resistance to conventional therapies. Identifying a novel therapeutic approach may improve the prognosis for patients with IBC. Because androgen receptor (AR)-expressing tumors may be targeted by anti-AR therapy, the authors examined the prevalence of AR expression in IBC tumors and explored its clinical relevance.

METHODS

Tissue microarrays of 88 IBC tumors were stained immunohistochemically with monoclonal antibody against AR, and the results were correlated with clinicopathologic parameters and survival outcomes.

RESULTS

The median follow-up was 10.8 years. AR was positive in 39% of the IBC tumors and in approximately one-third of estrogen receptor (ER)-negative and progesterone receptor (PR)-negative tumors. AR positivity was significantly associated with lymphovascular invasion (P = .01) but not with other clinicopathologic parameters. There was a trend toward an association between AR expression and PR expression (P = .07). In univariate survival analysis, patients who had AR-negative/ER-negative tumors had significantly worse overall survival (P = .03) and disease-specific survival (P = .04) than patients who had tumors with other combinations of AR/ER status.

CONCLUSIONS

AR expression was common in IBC tumors, and AR positivity was significantly associated with lymphovascular invasion. Patients who had AR-negative/ER-negative tumors had the worst survival outcomes. Further study with a larger series will be required to delineate the biologic mechanisms of AR and their clinical significance in IBC tumors. Cancer 2014;120:1775–1779. © 2014 American Cancer Society.

Ancillary